Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 13/20 | 0.55 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.45 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.44 |
| ▸ | CDKL5 | O76039 | 1/20 | 0.44 |
| ▸ | IKBKB | O14920 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.42 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24067801 | 0.91 | MET (0.45) | METMAP4K4PDPK1IKBKBKCNH2 | |
| SCHEMBL21171386 | 0.90 | MET (0.47) | METPDPK1CDKL5KCNH2MCHR1 | |
| SCHEMBL21171553 | 0.89 | MET (0.47) | METPDPK1CDKL5KCNH2 | |
| SCHEMBL21171387 | 0.89 | MAP4K4 (0.49) | METMAP4K4IKBKBKCNH2 | |
| SCHEMBL21171652 | 0.88 | MAP4K4 (0.48) | METMAP4K4IKBKBKCNH2 | |
| SCHEMBL21172009 | 0.88 | MET (0.47) | METPDPK1CDKL5KCNH2 | |
| SCHEMBL21171389 | 0.86 | MET (0.48) | METPDPK1CDKL5KCNH2 | |
| SCHEMBL21171388 | 0.85 | MET (0.49) | METPDPK1CDKL5KCNH2 | |
| SCHEMBL21171992 | 0.85 | MET (0.46) | METPDPK1CDKL5KCNH2 | |
| SCHEMBL21171378 | 0.84 | MET (0.49) | METCDKL5KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10590129-B2 | 3,5-disubstituted-3H-imidazo[4,5-B]pyridine and 3,5-disubstituted-3H-[1,2,3]triazolo[4,5-B] pyridine compounds as modulators of protein kinases | RHIZEN PHARMACEUTICALS SA (CH) | 2020-03-17 | — | — | US | disclosed |
| US-20190218211-A1 | NOVEL 3,5-DISUBSTITUTED-3H-IMIDAZO[4,5-B]PYRIDINE AND 3,5-DISUBSTITUTED -3H-[1,2,3]TRIAZOLO[4,5-B] PYRIDINE COMPOUNDS AS MODULATORS OF PROTEIN KINASES | RHIZEN PHARMACEUTICALS AG (CH) | 2019-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10590129-B2 | 3,5-disubstituted-3H-imidazo[4,5-B]pyridine and 3,5-disubstituted-3H-[1,2,3]triazolo[4,5-B] pyridine compounds as modulators of protein kinases | MAP4K2, MAP3K3, MAP3K1 | MET 1142/4885MAP4K4 35/4885PDPK1 78/4885 |
| US-20190218211-A1 | NOVEL 3,5-DISUBSTITUTED-3H-IMIDAZO[4,5-B]PYRIDINE AND 3,5-DISUBSTITUTED -3H-[1,2,3]TRIAZOLO[4,5-B] PYRIDINE COMPOUNDS AS MODULATORS OF PROTEIN KINASES | MAP4K2, MAP4K3, MAP3K1 | MET 1570/4885MAP4K4 28/4885PDPK1 65/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.